AKT1 and renal cell carcinoma: The efficacy of the PI3K/mTOR inhibitor NVP-BGT226 correlates well with recent studies that proposed Akt/mTOR inhibition as a promising therapeutic target for TFE3-fusion RCC [26, 40].